Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Starts Over On DTC “Principles”

Executive Summary

The Pharmaceutical Research & Manufacturers of America is starting with a clean slate as it works on voluntary guidelines for direct-to-consumer advertising

You may also be interested in...



PhRMA Finalizing Voluntary Guidelines On DTC Advertising

The Pharmaceutical Research & Manufacturers of America is putting the finishing touches on voluntary guidelines for direct-to-consumer advertising

PhRMA Finalizing Voluntary Guidelines On DTC Advertising

The Pharmaceutical Research & Manufacturers of America is putting the finishing touches on voluntary guidelines for direct-to-consumer advertising

FDA’s Crawford Praises DTC Advertising; PhRMA’s Tauzin Pushes For Change

FDA Acting Commissioner Lester Crawford is highlighting the benefits of direct-to-consumer advertising rather than the need for agency regulation of the practice

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel